Developer docs
API playgroundTry for free, no card

Search company profiles

BioGenerator

Full company profile

uuid0003djt

Namestring
BioGenerator
Legal namestring
BioGenerator
Websiteurl
biogenerator.org
Company typeenum
Private
Founded yearint
2003
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital funding, life sciences investment, bioscience startup incubation, seed stage investment, company building services
Industry2 codes
1Accelerators & Incubators (Investor-Operated)
CodeFSANAAAMPrimaryYes
2Healthcare & Life Sciences Growth Equity
CodeFSANACABPrimaryNo
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital and Startup Incubation
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

BioGenerator is a venture development organization that creates, builds, and invests in life sciences startups in human health and agriculture through two integrated components: BioGenerator Ventures (the investment arm providing catalytic seed and growth-stage capital) and BioGenerator Labs (the company-building engine providing technology, talent, proof of concept grants, coaching, grant training, and innovative laboratory space). The combined offering accelerates new ventures from concept through exit, with over $50M directly invested and $2.8B raised by portfolio companies across more than 80 active investments.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BioGenerator operates as a dual-entity organization consisting of two integrated offerings: BioGenerator Ventures (the investment arm that provides capital and catalytic funding to life sciences startups in human health and agriculture) and BioGenerator Labs (the company-building engine that provides operational resources including proof of concept grants, coaching, laboratory space, talent, and investor relations support). These two components work together, with Ventures providing funding and Labs providing the operational infrastructure to accelerate portfolio companies from formation through growth.

Product and service2 records
1BioGenerator Ventures
CategoryInvestment Arm
Description

The investment arm of BioGenerator that creates, builds, and invests in companies solving important problems in human health and agriculture. Provides catalytic investments to life sciences companies in therapeutics, diagnostics, medical devices, research tools, and agriculture technology. With over $50M invested into startups and $2.8B raised by portfolio companies, it serves as the equity capital component of BioGenerator's venture development platform, with more than 80 active investments across the portfolio.

2BioGenerator Labs
CategoryCompany-Building Resources
Description

A suite of company-building tools including technology, talent, proof of concept grants, coaching, grant training, and innovative laboratory space designed to accelerate new ventures. Services include SBIR/STTR non-dilutive grants, physical facilities, coaching, talent acquisition, and investor relations support provided to portfolio companies to complement BioGenerator Ventures' capital investments.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers6 records
1Johnson & Johnson Innovation (JLABS)
2BioEnterprise
TypeDirect peer
Description

BioEnterprise is a Cleveland-based life sciences business formation and acceleration organization that provides capital, management, and resources to early-stage bioscience companies, making it the most structurally similar regional life sciences venture development organization to BioGenerator.

3Cultivation Capital
TypeDirect peer
Description

Cultivation Capital is a St. Louis-based venture capital firm that has co-invested with BioGenerator in multiple rounds (Healthy Bytes, SweetSpot), serving as a regional peer in the same geographic ecosystem with overlapping life sciences and technology portfolios.

4IndieBio
TypeDirect peer
Description

IndieBio is a life sciences accelerator that combines seed capital with laboratory infrastructure and mentorship to launch biology-driven startups, directly comparable to BioGenerator's dual-arm model of investment plus BioGenerator Labs.

5MBC BioLabs
TypeDirect peer
Description

MBC BioLabs operates co-working laboratory facilities and provides venture capital-adjacent support to early-stage life sciences startups in the San Francisco Bay Area, directly comparable to BioGenerator's lab infrastructure and startup-building resources.

6Alexandria LaunchLabs
TypeDirect peer
Description

Alexandria LaunchLabs provides fully equipped laboratory and office space along with operational support to early-stage life sciences companies, comparable to BioGenerator Labs' co-working lab, mentorship, and company-building resources.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment82 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioGenerator

Venture Capital and Startup Incubationbiogenerator.org

BioGenerator firmographics

Firmographics
Name
BioGenerator
Legal name
BioGenerator
Website
https://biogenerator.org
Company type
Private
Founded year
2003
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

BioGenerator industry classification

Industry
Product category
Venture Capital and Startup Incubation
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171)
SIC
Investment Advice (6282)
akta.pro primary industry
Accelerators & Incubators (Investor-Operated) (FSANAAAM)
akta.pro secondary industry
Healthcare & Life Sciences Growth Equity (FSANACAB)

Keywords

  • Venture capital funding
  • Life sciences investment
  • Bioscience startup incubation
  • Seed stage investment
  • Company building services

Where BioGenerator is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioGenerator business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Distribution channels1 record

Marketing channels4 records

BioGenerator product offering

Product offering

Core offering

BioGenerator is a venture development organization that creates, builds, and invests in life sciences startups in human health and agriculture through two integrated components: BioGenerator Ventures (the investment arm providing catalytic seed and growth-stage capital) and BioGenerator Labs (the company-building engine providing technology, talent, proof of concept grants, coaching, grant training, and innovative laboratory space). The combined offering accelerates new ventures from concept through exit, with over $50M directly invested and $2.8B raised by portfolio companies across more than 80 active investments.

Product overview

BioGenerator operates as a dual-entity organization consisting of two integrated offerings: BioGenerator Ventures (the investment arm that provides capital and catalytic funding to life sciences startups in human health and agriculture) and BioGenerator Labs (the company-building engine that provides operational resources including proof of concept grants, coaching, laboratory space, talent, and investor relations support). These two components work together, with Ventures providing funding and Labs providing the operational infrastructure to accelerate portfolio companies from formation through growth.

Differentiator

Problem solved

Functional benefit

Products and services

  • BioGenerator Ventures The investment arm of BioGenerator that creates, builds, and invests in companies solving important problems in human health and agriculture. Provides catalytic investments to life sciences companies in therapeutics, diagnostics, medical devices, research tools, and agriculture technology. With over $50M invested into startups and $2.8B raised by portfolio companies, it serves as the equity capital component of BioGenerator's venture development platform, with more than 80 active investments across the portfolio.
  • BioGenerator Labs A suite of company-building tools including technology, talent, proof of concept grants, coaching, grant training, and innovative laboratory space designed to accelerate new ventures. Services include SBIR/STTR non-dilutive grants, physical facilities, coaching, talent acquisition, and investor relations support provided to portfolio companies to complement BioGenerator Ventures' capital investments.

Companies that use BioGenerator

Customer profile

Segments1 record

Ideal customer profiles1 record

BioGenerator technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

BioGenerator partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

BioGenerator competitors and assessment

Company assessment

Peers

Direct peers

  • BioEnterprise: BioEnterprise is a Cleveland-based life sciences business formation and acceleration organization that provides capital, management, and resources to early-stage bioscience companies, making it the most structurally similar regional life sciences venture development organization to BioGenerator.
  • Cultivation Capital: Cultivation Capital is a St. Louis-based venture capital firm that has co-invested with BioGenerator in multiple rounds (Healthy Bytes, SweetSpot), serving as a regional peer in the same geographic ecosystem with overlapping life sciences and technology portfolios.
  • IndieBio: IndieBio is a life sciences accelerator that combines seed capital with laboratory infrastructure and mentorship to launch biology-driven startups, directly comparable to BioGenerator's dual-arm model of investment plus BioGenerator Labs.
  • MBC BioLabs: MBC BioLabs operates co-working laboratory facilities and provides venture capital-adjacent support to early-stage life sciences startups in the San Francisco Bay Area, directly comparable to BioGenerator's lab infrastructure and startup-building resources.
  • Alexandria LaunchLabs: Alexandria LaunchLabs provides fully equipped laboratory and office space along with operational support to early-stage life sciences companies, comparable to BioGenerator Labs' co-working lab, mentorship, and company-building resources.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key highlights6 records

Customer concentration

BioGenerator social profiles

Digital presence

BioGenerator financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioGenerator leadership team

Management profile

Number of profiles

Profiles5 records

BioGenerator funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioGenerator M&A and investment

M&A and investment

M&A

Investments82 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioGenerator

What does BioGenerator do?

BioGenerator is a venture development organization that creates, builds, and invests in life sciences startups in human health and agriculture through two integrated components: BioGenerator Ventures (the investment arm providing catalytic seed and growth-stage capital) and BioGenerator Labs (the company-building engine providing technology, talent, proof of concept grants, coaching, grant training, and innovative laboratory space). The combined offering accelerates new ventures from concept through exit, with over $50M directly invested and $2.8B raised by portfolio companies across more than 80 active investments.

Is BioGenerator a public or private company?

BioGenerator is a private company. It is classified as unknown and is currently operating.

When was BioGenerator founded?

BioGenerator was founded in 2003. It employs 11 to 50 people.

Where is BioGenerator based?

BioGenerator is headquartered in St Louis, United States, in the North America region.

Who are BioGenerator's main competitors?

Johnson & Johnson Innovation (JLABS) is listed as a peer. Direct peers are BioEnterprise, Cultivation Capital, IndieBio, MBC BioLabs and Alexandria LaunchLabs.

Does BioGenerator have an API?

No public API is recorded for BioGenerator.

What industry is BioGenerator in?

BioGenerator's product category is Venture Capital and Startup Incubation. Its primary akta.pro industry code is FSANAAAM, Accelerators & Incubators (Investor-Operated), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 541714 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American City Business JournalsBioGenerator lands on Time list of top US incubators, acceleratorsBioGenerator, a St. Louis-based organization, ranked 43rd overall and second among health and life sciences-focused programs on Time's list of top US incubators and accelerators. The rankings were based on an evaluation of more than 2,000 founders.FinSMEsAllotera Therapeutics Raises $35M in FundingAllotera Therapeutics raised $35M in equity and venture debt, bringing its total funding to $150M. The company will use the funds to expand operations and R&D, including its lead CD7-targeted CAR-T therapy Sofi-cel. It also entered a strategic partnership with Blood Cancer United.Stock TitanAllotera closes $35M financing for CAR-T trialAllotera Therapeutics (formerly Wugen) has closed a $35 million financing round as an extension of its Series C, bringing total capital raised to $150 million, to advance its off-the-shelf CAR-T cell therapy Soficabtagene Geleucel (Sofi-cel) through the global pivotal T-RRex clinical trial for relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. The financing was led by Fidelity Management & Research Company with participation from Lightchain Capital, BioGenerator, and new investors including Blood Cancer United's Therapy Acceleration Program, while Banc of California provided the venture debt component. Allotera has also entered a strategic partnership with Blood Cancer United to access drug development expertise and clinical trial support as the company advances toward potential regulatory submission.BioSpaceAllotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell CancersAllotera Therapeutics closed a $35 million financing round, bringing total capital raised to $150 million. The funds will support the pivotal T-RRex trial of Soficabtagene Geleucel, an off-the-shelf CAR-T therapy for T-cell cancers. The company also entered a strategic partnership with Blood Cancer United.St. Louis Economic Development PartnershipMediBeacon Receives FDA Approval for Breakthrough ProductMediBeacon received FDA approval for its Transdermal GFR System, a non-invasive kidney function test using light on the skin. The system measures clearance of a fluorescent tracer and records 2.5 readings per second. The company partnered with BioGenerator and BioSTL on the technology.BiostlInsect Control AgTech Startup, a BioGenerator Portfolio Company, Raises $1MImpetus Agriculture, an AgTech startup, has successfully raised $1 million in seed financing to advance its biological insect control solutions, with the funding led by BioGenerator and The Yield Lab. The company has demonstrated its technology's effectiveness in controlling economically significant insects and has established a co-development agreement with a major agricultural company to commercialize its innovations. The new funding will facilitate further testing of its insect control technology and expand its capabilities.PR NewswireEric Gulve Announces Retirement as President of BioSTL Startup Arm BioGenerator; Charlie Bolten to Take the HelmDr. Eric Gulve has announced his retirement as President of BioGenerator, the startup arm of BioSTL, after 15 years in the role, effective January 1, 2023, though he will remain Executive Vice President of BioSTL until mid-2023. Charlie Bolten, currently Senior Managing Director, will succeed Gulve as President. Under Gulve's leadership since 2009, BioGenerator invested $39 million in over 100 St. Louis bioscience companies, which collectively raised more than $2.6 billion in follow-on capital, with 85 percent of that funding sourced from outside the St. Louis region.PR NewswireBioSTL and BioGenerator Partner with Xceede Solutions To Implement Program Management SolutionsXceede Solutions has been selected to partner with BioSTL and its investment arm BioGenerator to implement a program management platform for their economic development and venture investment activities in the St. Louis region. The platform will streamline internal data management, reporting, and workflow processes while supporting the broader innovation ecosystem. This partnership aims to enhance inclusion, diversity, and equity within St. Louis's startup community.FinSMEsEuclises Pharmaceuticals Completes Nearly $2M Series A FundingEuclises Pharmaceuticals, a St. Louis-based biotechnology company, completed a nearly $2M Series A funding round. Backers include Cultivation Capital, St. Louis Arch Angels, and BioGenerator, which had previously invested $1.3M. The company will use the funds to complete preclinical work and file an IND for first studies of lead candidate ECP-1014.GlobeNewswireNational Award of Excellence Presented to Six Organizations for Advancing Regional CompetitivenessSix organizations won SSTI's 2013 Excellence in TBED award at its annual conference in Portland, OR. The winners include USTAR, ICR, BioGenerator, UND Center, MLSC, and ASU EIG, with USTAR cited for a $488 million return on investment. The Most Promising TBED Initiative was ASU's Entrepreneurship & Innovation Group.